A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
In a letter to congressional leaders, the groups said they "believe strongly" that the FDA should play a critical role in developing a modernized framework.